Member Info for jimmy2011

no one claims to now value, but some have more exstentive information/ researsh than others, and with that are more able to put a price on something, and its only there opinion on a opinion board,
each individual makes there own mind up.
so it does not make them a lyer or a cheat.
gla

after being told to whine my neck in, ive whined it out and saying the deal is in the area of £ 400 mill, not £150 mill.
well done lth who kept the faith, averaged down and rode the new wave,
gla
p/s , nice to see igraine comeing back in play,

:)

Anfang des Jahres sah es auch ohne Pusherei sehr gut aus. Gute Zahlen, gute Investitionen, Management hat auch einen guten Eindruck gemacht.

Leider hat das Management später einige Fehler gemacht, daher ist der Kurs in London noch weiter gefallen.

Sie hätten ohne Weiteres ein Teil der Aktien zurückkaufen können und so langsam wieder mehr Investoren gewinnen können und nicht ständig Kapitalerhöhungen durchführen sollen, an sich ja nicht nötig, hätten mit dem Gewinn gut wirtschaften können.

Hab das hier noch nicht aufgegeben, es braucht aber noch viel viel mehr Geduld als ich zuerst dachte.

to new-bys and lth's,
took a large holding this am, to add to my position, off loaded a large % of my sarium as stated,
not that is anyones business, but , just like to let people know, im not a ramper, i put my money where my mouth is/ or is it information ???

place your bet/ make your choice.
genuin, gl all holders.

big dave, timing is the key,
well done all lth and beleivers,
today is just the begining,
wish all well,
keep the faith, and build, if affordable.
news soon,

if you invest in ciz, surley you have investment in vela, after all you have 5% in sgsc, vela has 9%,
all ****ing in same pot?
gla

i hold 2 mill of sarium @ 0.35, im selling tomorrow and adding to my 100 mill holding in here, thats how confident i am,
gla

look at the volume,
if 140 mill was a sell, we would be in the red today,
as all ways , big dave is looking at the big pic,
ciz tr1, is a bullish sign,
140 mill is a buy,
covid needs a treatment, and sgsc have one,
and we are invested along with a lot of others,
this is being worked for massive returns, and thous who hang in and build will make massive returns, you have to read between the lines.
gla

large holding taken in ciz,
is this a possible sign?
ciz have a investment in our trial , via sgsc.

to buy 50 mill on a 10% rise,
momentem is comeing back,
soon be back in the 0.08/0.09 ,
massive build/ top up time.
gla
hold the faith,

i have him bloked, lol is he biteing?

interesting read to all new investers,
so who do you trust??
mysteryguy, or these bunch of very succsesful bussines men?

as Chiroscience, Celsis, ReNeuron, Vectura, Biovex and Merlin Biosciences Ltd. Appointed an OBE in 1995 for services to medical bioscience, he was knighted in 2001 for services to bioscience and enterprise. Latterly he was founder of Arix Bioscience plc (LSE: ARX), of the oncology specialist Ellipses Pharma Limited, and of Excalibur Healthcare Services Ltd.

The Business:

Igraine targets innovative technologies and discoveries using an extensive network of scientific, industry, and academic contacts, including eminent scientists and key opinion leaders. Its network also enables it to pursue relationships with pharmaceutical companies which are both a potential source of innovative opportunities and potential acquirers.

The team has developed relationships over many years with leading universities and other academic and research institutions globally and maintains close working relationships with premier professional advisers and fund managers.

Igraine works with institutional and individual investment partners and has a formal co-investment agreement with Excalibur Healthcare Services Ltd.

Igraine has invested in Excalibur Medicines Ltd (“EML”), a subsidiary of Excalibur Healthcare Services Ltd. EML has secured exclusive rights to and owns the COVID-19 patents on a drug, AZD1656, which is being developed as a potential therapeutic for diabetics suffering from COVID-19.

As there are very few new therapeutics in development for COVID-19 and associated virally transmitted diseases (most research is in combining existing treatments), this has the potential to be highly attractive to big pharma and biotech buyers. Further, if the trials are successful, it is likely the drug will be effective for the general population in COVID -19 and in other respiratory diseases.

Developments Intended by the Company’s Financial Year-End:

Excalibur Medicines Limited, a subsidiary of Excalibur Healthcare Services Ltd., announced that the clinical team will report on the ARCADIA trial in September.

Excalibur Medicines Ltd (“EML”) has secured exclusive rights to and owns the patents on a drug, AZD1656, which is being developed as a potential therapeutic for people with diabetes suffering from COVID-19. The ARCADIA trial which took place across 31 sites was completed in July this year.

The research project was arranged and structured by Professor Sir Chris Evans, Chairman and CEO of Excalibur Healthcare Services, through its subsidiary, Excalibur Medicines Ltd. Sir Chris worked closely with Professor John Martin and his team at St George Street, a UK-based biomedical research charity, which secured the initial project and permission to run the trial from AstraZeneca.

The aim of the ARCADIA trial is to determine whether AZD1656 improves clinical outcomes in diabetic patients hospitalised with COVID-19. The World Health Organisation’s (WHO) 8-point Ordinal Scale for Clinical Improvement will be used as the standard methodology for measurin

Oscillate Plc - Interim Results For The Six Months Ended 31 May 2021
09/03/2021 | 05:05am EST
share with twitter
share with LinkedIn
share with facebook
3 September 2021

Oscillate PLC (Formerly known as DiscovOre PLC)
(“Oscillate”or the “Company")

Interim Results For The Six Months Ended 31 May 2021

Burns Singh Tennent-Bhohi, Chairman’s Statement

I am pleased to present the interim results for Oscillate plc (AQSE: MUSH) for the period ending 31 May 2021. Of most significance, and a defining moment for the Company during the period, was the completion of a £3,500,000 brokered placing led by the Company’s broker, Peterhouse Capital, and serial entrepreneur Chris Akers. In conjunction with this financing, the Company announced its intention to adopt a broader investment policy to include medical psychedelics, and the Board welcomed a new officer in Narisha Ragoonanthun, as Jeremy Ross resigned from the Board of Directors.

In the months to follow, the Company has been focusing heavily on creating and developing a premier alternative health investment issuer that can offer investors a unique blend of optionality.

Importantly, as the Company enters this emerging category of investment, a great degree of attention has been placed on ensuring that potential investment opportunities offer the ability to generate material value, but also credible alignment, as the Company builds important foundations that can position Oscillate to build a broad audience in a market with limited access in direct market exposure.

In July 2021, Oscillate completed its legal opinion, thereby enabling it to lawfully invest in the medical psychedelics industry and positioned as one of the first listed investment issuers within U.K. capital markets permitted to invest in opportunities consistent with the legal opinion.

Investment Positions & Commercial Activity Post 31 May 2021:

IGRAINE PLC (AQSE: KING)

28 June 2021

No. of Shares Held: 21,312,460

As a % of the Enlarged: 24.64%

About Igraine:

Chairman, Professor Sir Christopher Evans OBE

Professor Sir Christopher Evans is a renowned scientist and highly successful entrepreneur with numerous prestigious awards and medals for his work over the last 30 years during which time he has built more than 50 medical companies from start-up and floated 20 new medical businesses on stock markets in six different countries.

He has created 11 successful academic spin-outs and companies worth over $2.4 billion, and has raised $2.6 billion from disposals. He directed the raising of approximately $450 million for Merlin Biosciences Funds and $2.6 billion from disposals, including the sale of BioVex Group, Inc. to Amgen Inc. and Piramed Limited to Roche Group. Through Merlin Ventures Limited he co-founded and advised Biotech Growth Trust plc. Arakis Limited, one of the companies developed by Chris Evans, was sold to Sosei Co. Ltd for $187 million. Chris Evans has founded notable companies such

0.09 by new year minimum,
or,
0.04 as mystery guy wants.
????
this is bottem,
to sell at this stage of play is the only way you will lose money, do not fall for the derampers trap, planting there seed , day in, day out, day in , day out, grinding the weak down to sell, peaking at your head, day in, day out,
why oh why oh why , do they wish to share there wisdom? are they the good sermaritains of the aim stock exchange? looking after your interests?
wishing to go to heaven as a saint because of all the good deeds in life? saving you , a complete unknown lots of money on this investment,
oh thank you for your advice, i dont know how i would survive with out you, saints of the aim.

Is this the sign of news this week?
It's due and needed.
Gla

yes,

im sorry for my out burst, just caught up with comments and mystery pushed a button.
i appologize to fellow investers.
gla

listen hear you little ******, i can assure you i have not disapeared, and no coward, i stand by what i say, and am still buying , if you go back to my telegram post,( before banned) i stated croda as part of this circle, it was £48 a share, now hitting a £100,
why?
time will show.
so fxxxck off , pr///ick.